Premium Nahrungsergänzungsmittel | artgerecht

FGFR2b: Function, Cancer & Therapy

FGFR2b is an isoform of fibroblast growth factor receptor 2 that plays a key role in cell development, tissue repair, and the formation of certain cancers.

Regular tips about health Regular tips about health

Things worth knowing about "FGFR2b"

FGFR2b is an isoform of fibroblast growth factor receptor 2 that plays a key role in cell development, tissue repair, and the formation of certain cancers.

What is FGFR2b?

FGFR2b (fibroblast growth factor receptor 2b) is a specific isoform of the fibroblast growth factor receptor 2 (FGFR2). This receptor belongs to the family of receptor tyrosine kinases and is located on the surface of various cell types. The designation “b” refers to an alternative splice variant produced by differential RNA splicing of the FGFR2 gene; it is predominantly expressed in epithelial cells.

Biological Function

FGFR2b binds specifically to certain fibroblast growth factors (FGFs), particularly FGF7 (also known as keratinocyte growth factor, KGF) and FGF10. Upon ligand binding, the receptor activates an intracellular signaling cascade that controls multiple biological processes:

Cell growth and division (proliferation)
Cell migration and differentiation
Embryonic organ development (e.g., lung, skin, breast)
Tissue regeneration and wound healing
Maintenance of epithelial homeostasis

Clinical Significance

FGFR2b in Cancer

Alterations in the FGFR2b signaling pathway are highly relevant in various cancers. In particular, FGFR2 amplifications, mutations, and gene fusions have been identified in several tumor types:

Gastric cancer (gastric adenocarcinoma): FGFR2b is overexpressed in a significant proportion of cases.
Bladder cancer (urothelial carcinoma)
Breast cancer
Biliary tract cancer (cholangiocarcinoma)
Endometrial carcinoma

Overexpression or amplification of FGFR2b leads to uncontrolled receptor activation, which can promote tumor growth, metastasis, and resistance to certain therapies.

FGFR2b as a Therapeutic Target

Due to its role in oncogenesis, FGFR2b is an important target in cancer therapy. Several approaches are currently being investigated:

FGFR inhibitors: Small molecules that block the kinase activity of the receptor (e.g., erdafitinib, pemigatinib, futibatinib)
Monoclonal antibodies: Antibodies specifically targeting FGFR2b, such as bemarituzumab, which is being studied in clinical trials for FGFR2b-overexpressing gastric cancer
Antibody-drug conjugates (ADCs): Combinations of antibodies with cytotoxic agents for targeted tumor cell destruction

Diagnosis and Biomarkers

Determining the FGFR2b status of a tumor is essential for selecting appropriate therapies. The following diagnostic methods are used:

Immunohistochemistry (IHC): Detection of FGFR2b protein expression in tumor tissue
Fluorescence in situ hybridization (FISH): Detection of gene amplifications
Next-generation sequencing (NGS): Identification of mutations and gene fusions in the FGFR2 gene

These tests enable personalized cancer therapy (precision oncology), in which patients whose tumors harbor FGFR2b pathway alterations can be treated with targeted agents.

References

Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nature Reviews Cancer. 2010;10(2):116-129.
Meric-Bernstam F et al. Bemarituzumab in patients with FGFR2b-selected gastric/gastro-oesophageal junction adenocarcinoma. Cancer Discovery. 2022;12(9):2130-2141.
Katoh M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nature Reviews Clinical Oncology. 2019;16(2):105-122.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.